Rapidly rising pretransplant hematocrit and hematocrit > or = 30% signal independent risks for delayed function and primary nonfunction in primary cadaveric renal transplantation.
Schmidt
R
R
Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48202.
Kupin
W
W
Dumler
F
F
Venkat
K K
KK
Mozes
M
M
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D004359:Drug Therapy, Combination; D006400:Hematocrit; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3